Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974907 | 0.77 | — | — | |
| SCHEMBL19195028 | 0.77 | — | — | |
| SCHEMBL29203595 | 0.75 | — | — | |
| SCHEMBL13162008 | 0.75 | — | — | |
| SCHEMBL23798125 | 0.74 | IL1B (0.37) | IL1BPDPK1CFTRGRM1 | |
| SCHEMBL23798534 | 0.72 | PDPK1 (0.38) | IL1BPDPK1CFTRGRM1MEN1 | |
| SCHEMBL23798519 | 0.72 | IL1B (0.35) | IL1BPDPK1CFTR | |
| SCHEMBL25017479 | 0.67 | TSHR (0.58) | PDPK1MEN1ALDH1A1KMT2AFFAR1 | |
| Lactic Acid SCHEMBL19615593 | 0.67 | TP53 (0.42) | IL1BMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL22911355 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | IL1B 2104/4885PDPK1 73/4885CFTR 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.